Trials / Completed
CompletedNCT00088582
Study Comparing SOM230 Subcutaneously and Sandostatin Subcutaneously in Acromegalic Patients
A Multicenter, Randomized, Crossover, Open Label Dose Finding Study to Compare the Safety, Efficacy and PK/PD Relationship of Multiple Doses of SOM230 and Sandostatin in Acromegalic Patients
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 62 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
5 month study comparing SOM230 s.c. and Sandostatin s.c. in acromegalic patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pasireotide (SOM230), Octreotide (Sandostatin) |
Timeline
- Start date
- 2004-03-01
- Primary completion
- 2005-10-01
- First posted
- 2004-08-02
- Last updated
- 2016-11-07
Locations
5 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00088582. Inclusion in this directory is not an endorsement.